By no means is Merck (NYSE:MRK) a perfect company or a perfect stock. Admittedly there are legitimate concerns about the company's pipeline, its ability to ameliorate a big upcoming patent cliff, and the long-term relationship between for-profit health care companies and the federal government. All of that said, this stock has been stagnant long enough and value-oriented investors should consider this name as a long-term revaluation play. (For more on value investing, read The Value Investor's Handbook.)
Decent Third Quarter Results
To be sure, Merck is not going to blow anyone away with its top-line momentum. Merck posted 8% growth in reported sales growth this quarter, with growth more on the order of 3%, in constant currency terms. While Singulair remains a very significant drug with over 10% of sales, Januvia/Janumet is growing nicely into a number two platform and other newer compounds like Gardasil and Isentress are showing solid growth, as well.
Read the full Investopedia article here:
http://stocks.investopedia.com/stock-analysis/2011/Mercks-Penance-Has-Gone-On-Long-Enough-MRK-JNJ-LLY-PFE-FRX-ALXN-VRTX-NVO-GILD1031.aspx
No comments:
Post a Comment